Who is sponsoring NCT05188339?

NCT05188339 is sponsored by Chang Gung Memorial Hospital.

What drugs are being tested in NCT05188339?

Interventions in NCT05188339: 4% sodium citrate, heparin group.

What condition does NCT05188339 study?

NCT05188339 studies Central Venous Catheter Thrombosis, Renal Dialysis.

Is NCT05188339 still recruiting?

NCT05188339 is currently status unknown. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT05188339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter

Status unknown Phase 2, PHASE3 Last updated 25 July 2022

What this trial tests

Phase 2, PHASE3 trial testing 4% sodium citrate in Central Venous Catheter Thrombosis in 120 participants. Status unknown.

Timeline

20 July 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	120
Start date	20 July 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Taiwan

Drugs / interventions tested

4% sodium citrate
heparin group

Conditions studied

Central Venous Catheter Thrombosis — all drugs for Central Venous Catheter Thrombosis →
Renal Dialysis — all drugs for Renal Dialysis →

Sponsor

Chang Gung Memorial Hospital

Who can join

20 and older, any sex, with Central Venous Catheter Thrombosis or Renal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utilizing 4% sodium citrate vs. heparin as a lock solution in central venous hemodialysis catheter among hemodialysis patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05188339 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05188339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing